6. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
With an upside potential of 99.1% and a relative strength index (RSI) of 33.8, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands out as one of the most oversold AI stocks in the market. While analyst support remains strong, the stock is currently lacking investor confidence.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell to a new 52-week low of $2.85 on May 19, 2026. That placed fresh pressure on the stock, even as the company continues to advance its AI-native drug discovery platform and pipeline across oncology, rare disease, neuroscience, immunology, and other therapeutic areas. The stock is down nearly 30% year-to-date.
Amid the share price pressure, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter 2026 results and business updates on May 6, 2026.
Revenue came in at $6.5 million, compared with $14.7 million in the prior-year period, while net loss narrowed to $117.5 million from $202.5 million. The company ended the quarter with $665.2 million in cash, cash equivalents, and restricted cash, and reiterated guidance for less than $390 million in 2026 operational cash burn, supporting runway into early 2028 without additional financing.
Beyond the numbers, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) highlighted progress across several programs.
REC-1245 showed early safety and pharmacokinetic data in solid tumors, with no dose-limiting toxicities observed to date. REC-4881 showed Phase 2 efficacy signals in familial adenomatous polyposis, with FDA engagement underway and an update expected in the second half of 2026.
The company also dosed the first patient in a Phase 1 study of REC-4539, an AI-designed LSD1 inhibitor. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) said its OS platform continues to integrate AI across multimodal biology, precision design, and clinical development, supporting its end-to-end approach to drug discovery and development.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company focused on using AI, automation, and data science to industrialize drug discovery.
While we acknowledge the potential of RXRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 most oversold AI stocks according to analysts.
Disclosure: None. Follow Insider Monkey on Google News.
